Navigation Links
Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial
Date:8/30/2014

MARLBOROUGH, Mass., Aug. 30, 2014 /PRNewswire/ -- Boston Scientific has released the primary endpoint results from its NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial, the first and only randomized sham-controlled clinical trial investigating vagus nerve stimulation (VNS) for the treatment of heart failure patients.  Faiez Zannad, M.D., Ph.D., Professor of Therapeutics and Cardiology and Director of the Clinical Investigation Center at the Institut National de la Sante et de la Recherche Medicale presented the results at the 2014 European Society of Cardiology (ESC) Congress in Barcelona, Spain. The results will also be published in the European Heart Journal.

The study evaluated 96 New York Heart Association (NYHA) Class II-III patients with heart failure and an ejection fraction of less than 35%.  All patients continued receiving optimal medical treatment for heart failure, but were randomized 2:1 to treatment or sham (implanted device but not receiving therapy), respectively. 

The trial did not meet the pre-specified six month primary efficacy endpoint of a reduction in left ventricular end systolic diameter as assessed by a blinded echocardiography core laboratory. Quality of life metrics demonstrated significant symptomatic improvement despite the lack of a significant effect on primary and secondary endpoint measures of cardiac remodeling and functional capacity in HF patients.

"The careful design and execution of NECTAR-HF has resulted in high quality data that will improve the understanding of the role of VNS in the treatment of patients with heart failure," said Prof. Zannad, NECTAR-HF Principal Investigator.  "Although patients receiving therapy reported feeling better as assessed by quality of life questionnaires, the application of VNS failed to reveal clear benefit when compared to sham, because the effect of therapy was no better t
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medical Device Developers - Network at BIOMEDevice Boston Next Week
2. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
3. Boston Scientific and Philips Healthcare Announce Collaboration to Enhance Imaging Equipment Offering
4. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
5. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
6. Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent
7. Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
8. Clean Room Environmental Best Practices for Medical Device & Pharmaceutical Manufacturers are Focus of Boston Seminar on June 6
9. Boston Scientific Increases Longevity Projections for Its U.S. Defibrillators
10. Boston Scientific Closes Cameron Health Acquisition
11. Cumberland Pharmaceuticals To Present At The 2012 Wells Fargo Securities Healthcare Conference In Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015  CytomX Therapeutics, Inc., a ... cancer, today announced the filing of a registration statement ... Commission (SEC) relating to a proposed initial public offering ... be offered and the price range for the offering ... its common stock under the symbol "CTMX" on the ...
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Tobramycin Market, 2010-2019" report ... antibiotic whose eye drop and ointment are the most ... or inflammation caused by eye infection. Currently, dozens of ... to produce tobramycin, among which the Top 5 are ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Developed by Pharmacia ... prostaglandin receptor agonist which effectively reduces intraocular pressure. ... FDA, latanoprost (under the trade name of Xalatan) ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Tobramycin Market, 2015-2019 2China Latanoprost Market Investigation Report 2015-2019 2
... Dec. 14, 2010 Samplify Systems, Inc., a ... the ultrasound market, is pleased to announce that ... has won Electronic Design Magazine,s Best ... category.  Details of Samplify,s AutoFocus™ beamforming technology currently ...
... 14, 2010 Pacira Pharmaceuticals, Inc. ... the New Drug Application (NDA) for EXPAREL™, a long-acting ... filing by the U.S. Food and Drug Administration (FDA). ... the initial indication of postsurgical analgesia by local administration. ...
Cached Medicine Technology:Samplify's AutoFocus™ Beamforming Technology Awarded Electronic Design's 'Best of 2010' 2
(Date:8/31/2015)... ... 2015 , ... On Saturday, July 11, 2015, during the annual New York ... NYSATA was proud to recognize Dr. Merritt F. Spear as the 2015 recipient of ... after long-time NYSATA member and Ithaca College athletic trainer and educator, is considered for ...
(Date:8/31/2015)... ... ... Intellitec Solutions announced they have reached a record for the number of new ... 2015. With the potential for more hiring occurring before the year end, this marks ... Dynamics CRM and Intacct, and has hired new support staff in all 4 of ...
(Date:8/31/2015)... Minneapolis, MN (PRWEB) , ... August 31, 2015 , ... ... The vasectomy has one of the lowest failure rates among birth control methods. Moreover, ... vasectomy. Still, some men hesitate to have their vasectomy done because they are ...
(Date:8/31/2015)... New York, NY (PRWEB) , ... August 31, ... ... solutions for plastic surgery, dermatology and women’s health, is proud to announce South ... system. Now expanding patient access to the most sought-after radio frequency thermotherapy ...
(Date:8/31/2015)... ... August 31, 2015 , ... GenHart Software, LLC, a rising ... to help small businesses operate as efficiently and cost effectively as possible, with a ... impact in their first year of operation – and the Charleston business community is ...
Breaking Medicine News(10 mins):Health News:NYS Athletic Trainers' Association Presents Recognition Awards at Annual Conference 2Health News:NYS Athletic Trainers' Association Presents Recognition Awards at Annual Conference 3Health News:Intellitec Solutions Achieves Record Pace for New Hiring 2Health News:One Stop Medical Center of Twin Cities Achieves Zero Failure Rate and Infection Rate in No Scalpel Vasectomy 2Health News:Thermi Heats Up South Korea Announcing Global Expansion with NewRegulatory Approvals for ThermiRF™ 2Health News:GenHart Software, LCC Launches Scheduling, Appointment Reminder, Text Marketing Software Designed to Help Businesses Increase Revenue While Decreasing Client Attrition 2Health News:GenHart Software, LCC Launches Scheduling, Appointment Reminder, Text Marketing Software Designed to Help Businesses Increase Revenue While Decreasing Client Attrition 3
... and 10-year survival rates continue to improve for children ... acute lymphoblastic leukemia (ALL), acute non-lymphoblastic leukemia, or non-Hodgkin ... the September 9 online issue of the Journal ... treatment for childhood hematologic malignancies have led to increased ...
... of Familial Risk Estimates Increases Estimated Melanoma Risk But ... relative risk of familial melanoma increases substantially when researchers ... cohort study. The relative risk of familial lung, breast, ... the correction. , Researchers have used the Swedish Cancer ...
... of daily calcium supplements show a marked reduction in lead ... role in reducing fetal and infant exposure. , A new ... take 1,200 milligrams of calcium daily have up to a ... lead-glazed ceramics and those with high bone lead levels showed ...
... Both higher fish consumption and longer breastfeeding are linked ... to a study of mothers and infants from Denmark. ... , "These results, together with findings from other studies ... provide additional evidence that moderate maternal fish intake during ...
... can be given in tandem with clot-dissolving drug , , ... give the clot-dissolving drug tPA to people with very ... a new study indicates. , The American Heart Association ... of tPA, tissue plasminogen activator, in such cases, "but ...
... Leadership Development and Technological Efficiency , ... ... 2008 -- http://www.jacksonhealthcare.com/companies.aspx [Jackson Healthcare] (JH) has ... http://www.locumtenens.com/new_leader08 [LocumTenens.com]. Working with the physician recruitment ...
Cached Medicine News:Health News:5- and 10-year survival continues to improve for US children with hematologic malignancies 2Health News:Also in the Sept. 9 JNCI 2Health News:Also in the Sept. 9 JNCI 3Health News:Calcium during pregnancy reduces harmful blood lead levels 2Health News:Eating fish while pregnant, longer breastfeeding, lead to better infant development 2Health News:Eating fish while pregnant, longer breastfeeding, lead to better infant development 3Health News:Blood Pressure Treatment Can Be Used Against Stroke 2Health News:R. Shane Jackson Named President of LocumTenens.com 2Health News:R. Shane Jackson Named President of LocumTenens.com 3
Cold light source single outlet....
... The 4150S is a state ... halogen light source with an ... standard coupler to connect optical ... source distinguishes itself from all ...
The 9300XSP is the brightest light source available. Visualize more clearly, see color more accurately, and work more effectively. Luxtecs xenon lighting delivers bright, white light that is as close...
The Carl Zeiss Head-worn Loupes L and LC are the ideal solution if a low magnification suffices for your work and you want to keep your hands free to perform the task at hand....
Medicine Products: